Terms: = Prostate cancer AND LIFR, SJS2, 3977, ENSG00000113594, SWS, STWS, CD118 AND Treatment
5 results:
1. Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.
Verma S; Kushwaha PP; Shankar E; Ponsky LE; Gupta S
Prostate; 2022 Oct; 82(14):1389-1399. PubMed ID: 35821621
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
Lee RT; Kwon N; Wu J; To C; To S; Szmulewitz R; Tchekmedyian R; Holmes HM; Olopade OI; Stadler WM; Von Roenn J
Cancer; 2021 Jun; 127(11):1827-1835. PubMed ID: 33524183
[TBL] [Abstract] [Full Text] [Related]
3. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract] [Full Text] [Related]
4. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Godoy-Tundidor S; Cavarretta IT; Fuchs D; Fiechtl M; Steiner H; Friedbichler K; Bartsch G; Hobisch A; Culig Z
Prostate; 2005 Jul; 64(2):209-16. PubMed ID: 15712220
[TBL] [Abstract] [Full Text] [Related]
5. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract] [Full Text] [Related]
